HER 2 status in invasive breast cancer: immunohistochemistry, fluorescence in-situ hybridization and chromogenic in-situ hybridization.
Indian J Pathol Microbiol
; 55(2): 175-9, 2012.
Article
in En
| MEDLINE
| ID: mdl-22771638
ABSTRACT
INTRODUCTION:
HER2/neu gene status in breast cancers can be evaluated by targeting protein and gene - immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH). Recent studies have shown chromogenic in-situ hybridization (CISH) as a relatively cheaper alternative. MATERIALS ANDMETHODS:
Forty-three nonconsecutive, randomly selected primary invasive breast cancer cases were evaluated for c-erbB-2 (HER2 protein) by IHC and gene amplification by FISH and CISH. Results of each of the same were compared.RESULTS:
CISH showed approximately 90% and 100% concordance for IHC negative and positive cases, respectively; while approximately 94.4% and 91% concordance with FISH amplified and non-amplified cases, respectively.CONCLUSION:
This study showed feasibility of incorporation of CISH as a low cost option in routine management of breast carcinoma in the Indian setting. Secondly, reconfirmation of IHC negative and positive cases can be done by CISH.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pathology
/
Breast Neoplasms
/
Immunohistochemistry
/
In Situ Hybridization
/
Receptor, ErbB-2
Type of study:
Diagnostic_studies
/
Evaluation_studies
Limits:
Female
/
Humans
Country/Region as subject:
Asia
Language:
En
Journal:
Indian J Pathol Microbiol
Year:
2012
Document type:
Article
Affiliation country:
India